

alzchem group

AGILE SCIENCE PURE RESULTS

Alzchem Group AG

QUARTERLY STATEMENT Q3 2026

Alzchem at a Glance

SALES IN € MILLION

9M 2025 ~ 425

9M 2026 ~ 444

EBITDA IN € MILLION


9M 2025 ~ 86

9M 2026 ~ 93


MARKETS

- HUMAN NUTRITION
- ANIMAL NUTRITION
- FINE CHEMISTRY
- PHARMA
- AGRICULTURE
- RENEWABLE ENERGY
- METALLURGY
- CUSTOM SOLUTIONS
- AGRI SOLUTIONS
- AUTOMOTIVE
- DEFENSE

EBITDA MARGIN BY MAIN SEGMENTS



THREE REPORTING SEGMENTS



70% SPECIALTY CHEMICALS

Production and distribution of high-quality chemical products

25% BASICS & INTERMEDIATES

Production of chemical intermediates for direct sale or refinement as specialty chemicals products

5% OTHER & HOLDING

Other activities, mainly services related to the chemical parks Trostberg and Hart

Content

1. Development of the Group 7
   - 1.1 Significant developments in the 9-month period from January 1 to September 30, 2026 7
   - 1.2 Nitroguanidine capacity expansion in Germany implemented according to plan 8
   - 1.3 U.S. Project: site selection completed and basic engineering in optimization phase 8
   - 1.4 Creatine business: sustained high demand underlines the strategic importance of capacity expansion 8
   - 1.5 Calcium cyanamide: decision in EU restriction proceedings still pending 9
   - 1.6 Share buyback completed and conversion to registered shares implemented as planned; additional share buyback program approved 9
   - 1.7 Non-recurring effects from customer grants received 10
   - 1.8 Results of operations 11
   - 1.9 Financial position 14
   - 1.10 Net assets 16
2. Development in the segments 18
   - 2.1 Specialty Chemicals segment 18
   - 2.2 Basics & Intermediates segment 19
   - 2.3 Other & Holding segment 20
3. Sustainability at Alzchem 21
4. Forecast report 24
5. Events after the balance sheet date 25

List of abbreviations 25
Financial calendar 2027 26
Remarks 26
Imprint 26

INTERACTIVE PDF

This PDF document is optimized for display with Adobe Acrobat and for use on screen. You can navigate both via the table of contents as well as via the navigation buttons in the upper right corner.

TABLE OF CONTENTS

PAGE BACK

PAGE FORWARD

FURTHER LINK

Alzchem grows in sales and EBITDA through the first nine months of 2026; specialty chemicals business continues strong performance; full-year outlook reaffirmed

- Group sales rise 4% to just under EUR 444 million
- EBITDA climbs 8% to over EUR 93 million
- EBITDA margin increases from 20.3% to 21.0%
- High-value ingredients in the Specialty Chemicals segment continue to drive growth: sales rise by 11% and EBITDA by 17%
- Basics & Intermediates impacted by weak demand from the pharmaceutical and agricultural sectors; metallurgy business continues to perform well
- Status of strategic investment projects:
  - Expanded nitroguanidine capacity in Germany in technical commissioning
  - U.S. project in the cost and planning optimization phase following completion of basic engineering
  - Necessary expansion of creatine capacity is proceeding according to plan
- Q3 2026 slightly weaker than previous quarters, as forecast
- Full-year growth forecast for 2026 confirmed
- Share buyback program successfully completed; new buyback program initiated with a volume of up to EUR 20 million


Note: Unless otherwise indicated, all amounts are stated in EUR thousand. For computational reasons, rounding differences of ± one unit may occur in tables.


KEY FIGURES OF THE ALZCHEM GROUP

Key figure	Unit	3rd quarter 2025	3rd quarter 2026	January 1 – September 30, 2025	January 1 – September 30, 2026
Sales	EUR thousand	**137,266**	**139,882**	**424,825**	**443,785**
EBITDA	EUR thousand	**29,724**	**28,698**	**86,183**	**93,184**
EBITDA margin	%	**21.7**	**20.5**	**20.3**	**21.0**
EBIT	EUR thousand	**23,069**	**19,142**	**66,541**	**69,433**
Result for the period	EUR thousand	**16,337**	**13,547**	**46,849**	**48,372**
Earnings per share (undiluted and diluted)*	EUR	**1.61**	**1.34**	**4.62**	**4.77**
Equity ratio	%	**40.0**	**41.6**	**40.0**	**41.6**


* In 2025, the calculation was based on the average number of outstanding shares of 10,106,189 for the period from January 1 to September 30, 2025, and 10,102,730 for the period from July 1 to September 30, 2025.
For the reporting period 2026, the calculation was made based on the average number of outstanding shares of 10,109,828 for the period from January 1 to September 30, 2026, and 10,082,118 for the period from July 1 to September 30, 2026.


SALES AND EBITDA SHARE BY SEGMENT IN THE NINE-MONTH PERIOD FROM JANUARY 1 TO SEPTEMBER 30, 2026





CHANGE IN SALES COMPARED TO THE PREVIOUS YEAR





1. Development of the Group

1.1 SIGNIFICANT DEVELOPMENTS IN THE 9-MONTH PERIOD FROM JANUARY 1 TO SEPTEMBER 30, 2026

Alzchem remains on its expected growth trajectory. Key drivers were the high-quality specialty chemical ingredients. Sustained strong demand in the food and defense sectors once again bolstered sales and profitability. By contrast, the market environment in the agricultural and pharmaceutical sectors remained challenging. At the same time, Alzchem consistently pursued its strategic capacity expansions.

In the first nine months of 2026, Alzchem increased Group sales by 4% from EUR 424.8 million to EUR 443.8 million. EBITDA rose by 8% from EUR 86.2 million to EUR 93.2 million, while the EBITDA margin increased from 20.3% to 21.0%. Given the higher energy and raw material prices, as well as scheduled start-up expenses for the new nitroguanidine capacities, this earnings performance is extremely encouraging. As announced, sales in the third quarter of 2026 were lower than in the previous quarters of 2026. This was primarily due to sales that were recognized earlier in the first half of the year, which had originally been projected for the third quarter.

The varying performance of the business segments is reflected in the segment figures. The growth segment Specialty Chemicals increased sales by 11% from EUR 281.6 million to EUR 312.7 million. EBITDA rose by 17% from EUR 78.0 million to EUR 91.5 million. Growth momentum came in particular from the Human Nutrition division with the creatine brands Creapure® and Creavitalis®, as well as from the defense business. This development confirms and reinforces the key investment decisions made to drive growth in both areas.

The Basics & Intermediates segment, by contrast, continued to be characterized by subdued demand in key markets. Business with the pharmaceutical and agricultural industries, in particular, suffered from weak market conditions, challenging operating environments, and intense international competition. Consequently, segment sales fell by 10% from EUR 121.6 million to EUR 109.5 million. The metallurgy business, on the other hand, showed a positive trend. A major event so far this year was the comprehensive renovation of the carbide furnace. With the help of the second furnace and proactive inventory management, Alzchem was able to ensure customer supply during the work. Following the one-time effects resulting from the renovation, the segment returned to positive EBITDA in the third quarter. In the first nine months, however, segment EBITDA of EUR 2.0 million remained below the EUR 5.1 million recorded in the prior year.

The weak industrial economy in parts of Europe, macroeconomic uncertainties, and volatile procurement costs remained key influencing factors. International supply chains proved to be largely stable during the reporting period. Alzchem factored higher raw material and transportation costs, as well as tariffs, into its pricing wherever possible. Based on the positive 9-month performance, the Management Board confirms its forecast for 2026 with Group sales of approximately EUR 600 million, EBITDA of approximately EUR 126 million, and an EBITDA margin of approximately 21.0%.

1.2 NITROGUANIDINE CAPACITY EXPANSION IN GERMANY IMPLEMENTED ACCORDING TO PLAN

With the expansion of production capacity for guanidine nitrate and nitroguanidine in Germany, Alzchem is advancing one of its key investment projects in the defense sector. The additional capacity is intended to enable the company to meet rising customer demand for nitroguanidine with larger supply volumes in the future.

After construction and installation work proceeded largely according to plan in the first half of the year, technical commissioning began in the third quarter. Following the scheduled production ramp-up, qualification batches were produced. While the expanded capacities did not yet generate additional sales in the first nine months of 2026, scheduled start-up expenses were incurred. With commissioning now complete, Alzchem is expected to be able to make the expanded nitroguanidine capacities available even before the customer's production is fully ramped up. The timing of additional sales and earnings contributions therefore depends largely on when customers ramp up their production capacities and purchase correspondingly larger volumes. The first sales from the new plant facilities will take place as early as Q4 2026. The expected increase in delivery volumes will contribute increasingly to profitable growth in the Specialty Chemicals segment in the future.

1.3 U.S. PROJECT: SITE SELECTION COMPLETED AND BASIC ENGINEERING IN OPTIMIZATION PHASE

Alzchem further advanced preparations for its own nitroguanidine production in the U.S. during the first nine months of 2026. In July 2026, the decision was made to locate the facility in Bushy Park, South Carolina. The planned production facility is intended to enable closer supply to the U.S. defense market in the future. The necessary precursors will continue to be supplied from Germany.

With the completion of basic engineering, the project reached another planning milestone during the reporting period. Building on this foundation, the focus is now on optimizing the technical design and further refining the cost and production planning for the U.S. site. At the same time, discussions with the U.S. Department of Defense regarding the specific details and amount of investment funding are in their final phase. The project's future course therefore also depends on the outcome of these negotiations.

1.4 CREATINE BUSINESS: SUSTAINED HIGH DEMAND UNDERLINES THE STRATEGIC IMPORTANCE OF CAPACITY EXPANSION

Demand for the premium creatine products Creapure® and Creavitalis® remained very high in the first nine months of 2026. Alzchem is benefiting in particular from the sustained interest in high-quality creatine "Made in Germany" in the established application areas of sports, nutrition, and health, and is developing new areas of application that provide additional growth momentum.

To tap into the market potential with additional sales volumes in the future, Alzchem continued to advance the investment program totaling approximately EUR 120 million – approved at the end of 2025 – during the reporting period. The program includes the expansion of production capacities for creatine and its precursors, as well as the associated infrastructure. Construction work on the new, largely automated production facility continued according to plan in the third quarter. Commissioning is still scheduled to take place in several phases starting in the second half of 2027.

With the additional capacity, Alzchem intends to meet the persistently strong demand with higher sales volumes in the future, generate additional sales and earnings contributions, and thereby further support profitable growth in the Specialty Chemicals segment.

1.5 CALCIUM CYANAMIDE: DECISION IN EU RESTRICTION PROCEEDINGS STILL PENDING

Alzchem views the latest developments in the REACH restriction proceedings for calcium cyanamide very positively. On October 22, 2026, another significant step in the process was taken: The REACH Regulatory Committee, in which the EU member states are represented, adopted the European Commission's new proposal by a clear majority and without any dissenting votes. This proposal provides that calcium cyanamide may continue to be used as a fertilizer in the future, with its use targeted at professional users. However, the process is not yet complete; the European Parliament and the Council have yet to review the matter.

1.6 SHARE BUYBACK COMPLETED AND CONVERSION TO REGISTERED SHARES IMPLEMENTED AS PLANNED; ADDITIONAL SHARE BUYBACK PROGRAM APPROVED

Alzchem successfully completed the share buyback program approved in December 2025 in August 2026. From August 5 to 18, 2026, the company acquired a total of 62,311 treasury shares on the stock exchange at a purchase price of approximately EUR 10.0 million, thereby fully utilizing the allocated buyback budget. The shares are to be used primarily to launch a new employee participation program.

In addition, Alzchem completed, as planned, the conversion from bearer shares to registered shares, as approved by the Annual General Meeting on May 5, 2026. Since September 17, 2026, the shares have been traded under the ISIN DE000A41YHG1 and the ticker symbol ACT0. The conversion took place on a 1:1 basis. The number of shares outstanding and shareholder rights remained unchanged.

On October 27, 2026, the Management Board, with the approval of the Supervisory Board, resolved to implement another share buyback program in the amount of up to EUR 20 million. The purpose of the buyback is to use the acquired shares as consideration for acquisitions, to distribute them to employees of the Alzchem Group, or to cancel the shares. This does not preclude other purposes permitted by law.

The buyback will be conducted in accordance with the terms of the authorization granted by the Annual General Meeting of 2024 and Delegated Regulation (EU) 2016/1052.

1.7 NON-RECURRING EFFECTS FROM CUSTOMER GRANTS RECEIVED

In the nine-month period of 2026, Alzchem received payments as part of the contractually agreed customer grants for the capacity expansion of nitroguanidine production in Germany. These payments significantly impact certain key figures of Alzchem and are therefore explained separately and in summary here.

IMPACT ON THE CASH FLOW STATEMENT

In accordance with IFRS accounting regulations, the customer grants received must be reported in operating cash flow. Consequently, operating cash flow was significantly impacted by the customer grants received. In the nine-month period of 2026, Alzchem received additional customer prepayments totaling EUR 11,427 thousand (nine-month period of 2025: EUR 55,537 thousand), which increased operating cash flow by this amount.

IMPACT ON THE BALANCE SHEET

The contractual arrangement and customer prepayments have a significant impact on Alzchem's balance sheet in the form of a corresponding increase in both total assets and total liabilities: Specifically, these are the balance sheet items "other receivables and other assets" on the assets side and "contract liabilities" on the liabilities side of the balance sheet. The balance sheet item "other receivables and other assets" includes receivables from future customer payments if the contractual arrangements provide for regular payments from customers for which no further conditions need to be met. These receivables are reduced by customer payments and are reported as either current or non-current receivables depending on their maturity. As of September 30, 2026, EUR 11,936 thousand (December 31, 2025: EUR 20,578 thousand) was reported in non-current and EUR 11,386 thousand (December 31, 2025: EUR 10,381 thousand) in current other receivables and other assets.

All customer grants received for this investment project are initially recognized as contract liabilities on the liabilities side of the balance sheet in accordance with IFRS. This also applies to the receivables from future customer grants reported under "other receivables and other assets." As the primary consideration for these customer grants, Alzchem must fulfill its commitment to provide additional production capacity for the delivery of products (nitroguanidine) from the new production facility subsidized by the customers – this obligation constitutes the contract liability. As soon as these additional quantities can be delivered, the contract liability will be released over the respective term of the individual customer contract in accordance with the quantities to be delivered each year as part of revenue recognition. This revenue recognition complies with the requirements of IFRS 15, occurs in addition to the revenue actually invoiced to customers and not significantly before the fiscal year 2027. As of September 30, 2026, a total of EUR 84,754 thousand (December 31, 2025: EUR 88,099 thousand) from this project was reported under non-current contract liabilities and EUR 8,398 thousand (December 31, 2025: EUR 1,303 thousand) under current contract liabilities.

The recognition of these balance sheet items also affects the balance sheet total and, consequently, the Group's equity ratio. As of September 30, 2026, Alzchem's balance sheet total increased by EUR 93,152 thousand (December 31, 2025: EUR 89,402 thousand) due to these special effects.

IMPACT ON THE INCOME STATEMENT

In the nine-month period of 2026, customer grants had only a very minor impact on the income statement. To date, only minor interest income resulting from the compounding of interest on customer grants has been recognized in the income statement.

1.8 RESULTS OF OPERATIONS

CONSOLIDATED INCOME STATEMENT (IFRS, UNAUDITED)

in EUR thousand	3rd quarter 2025	3rd quarter 2026	January 1 – September 30, 2025	January 1 – September 30, 2026
Sales revenue	**137,266**	**139,882**	**424,825**	**443,785**
Change in inventories of finished goods and work in progress	624	-6,259	15,493	-13,261
Other operating income	3,806	6,349	14,076	19,726
Cost of materials	-43,769	-41,100	-155,297	-134,235
Personnel expenses	-43,245	-42,620	-129,289	-134,397
Other operating expenses	-24,958	-27,554	-83,625	-88,434
EBITDA	**29,724**	**28,698**	**86,183**	**93,184**
Depreciation and amortization	-6,655	-9,556	-19,642	-23,751
EBIT	**23,069**	**19,142**	**66,541**	**69,433**
Other interest and similar income	819	929	2,156	1,485
Interest and similar expenses	-1,254	-1,522	-3,817	-4,444
Financial result	**-435**	**-593**	**-1,661**	**-2,959**
Result from ordinary business activities	**22,634**	**18,549**	**64,880**	**66,474**
Taxes on income and earnings	-6,297	-5,002	-18,031	-18,102
Consolidated result for the period	**16,337**	**13,547**	**46,849**	**48,372**
thereof non-controlling interests	43	43	129	128
thereof shares of the shareholders of Alzchem Group AG	16,294	13,504	46,720	48,244
Earnings per share in EUR (undiluted and diluted)*	**1.61**	**1.34**	**4.62**	**4.77**

* In 2025, the calculation was based on the average number of outstanding shares of 10,106,189 for the period from January 1 to September 30, 2025, and 10,102,730 for the period from July 1 to September 30, 2025.
For the reporting period 2026, the calculation was made based on the average number of outstanding shares of 10,109,828 for the period from January 1 to September 30, 2026, and 10,082,118 for the period from July 1 to September 30, 2026.

DEVELOPMENT IN THE 9-MONTH PERIOD FROM JANUARY 1 TO SEPTEMBER 30, 2026

In the 9-month period of fiscal year 2026, Alzchem generated sales of EUR 443,785 thousand, representing an increase of EUR 18,960 thousand, or 4%, compared to the same period last year. At the Group level, this performance was driven by higher sales volumes (1.0%) and increased selling prices (4.2%), while negative currency effects (-0.7%) had a slight offsetting effect. The Specialty Chemicals segment continued to perform particularly well, increasing its sales by EUR 31,124 thousand compared to the previous year. In contrast, the Basics & Intermediates and Other & Holding segments recorded a decline in sales, as expected.

Cost of materials was significantly lower than in the same period of the previous year due to volume factors. Taking changes in inventories into account, the "extended cost of materials ratio" ((cost of materials +/- change in inventories of finished goods and work in progress) / sales revenue) remained fairly stable at 33.2%, in line with the previous year's level of 32.9%. This is all the more encouraging given the current high energy and raw material costs. To ensure a steady supply of carbide, inventories were strategically built up in 2025 in preparation for the carbide furnace renovation. The measures were carried out successfully and according to plan in the first nine months of 2026.

Other operating income exceeded the prior-year level by EUR 5,650 thousand, driven primarily by higher capitalized in-house work resulting from increased investment activity.

Personnel expenses amounted to EUR 134,397 thousand in the first nine months of fiscal year 2026, an increase of EUR 5,108 thousand, or 4%, compared to the same period last year. In addition to the company's growth, collective bargaining adjustments contributed significantly to this increase. The wage increase of 4.85%, which took effect only in April of the prior year, was reflected for the first time in 2026 over the entire 9-month period.

Other operating expenses totaled EUR 88,434 thousand, exceeding the prior-year figure by EUR 4,809 thousand. This was driven in particular by higher waste disposal costs resulting from increased production volumes, as well as additional maintenance expenses associated with the carbide furnace renovation. Lower foreign exchange losses from currency valuation had an offsetting effect.

Alzchem continued its positive earnings trend in the first nine months of fiscal year 2026, increasing EBITDA by 8% or EUR 7,001 thousand to EUR 93,184 thousand. At the same time, the EBITDA margin improved from 20.3% to 21.0%.

Particularly as a result of the new nitroguanidine plant now having been commissioned, depreciation and amortization increased as scheduled by EUR 4,109 thousand to EUR 23,751 thousand during the reporting period.

The financial result amounted to EUR -2,959 thousand, compared to EUR -1,661 thousand in the prior year. This development is primarily attributable to two factors: First, interest income from cash investments decreased due to increased investment activity and the resulting reduction in liquidity available for investment. Second, non-cash interest rate changes in the valuation of non-current provisions led to a higher expense.

In the first nine months of fiscal year 2026, tax expense amounted to EUR 18,102 thousand (previous year: EUR 18,031 thousand). The slight increase reflects the higher earnings before taxes, while the Group tax rate remained virtually stable at 27% compared to 28% in the previous year.

Overall, Alzchem reported a consolidated result for the period of EUR 48,372 thousand for the first nine months of 2026, representing an increase of 3% compared to the same period last year (EUR 46,849 thousand).

This positive earnings trend is also reflected in earnings per share, which rose from EUR 4.62 to EUR 4.77 during the reporting period. The calculation was based on a weighted average of 10,106,189 shares outstanding for the period from January 1 to September 30, 2025, and on 10,109,828 shares for the corresponding period in 2026.

DEVELOPMENT IN THE THIRD QUARTER OF 2026

Alzchem continued its growth trajectory in the third quarter of 2026 as well, increasing sales by EUR 2,616 thousand compared to the same quarter of the previous year to EUR 139,882 thousand. The Specialty Chemicals and Other & Holding segments contributed to this positive development, while Basics & Intermediates recorded a decline as expected.

The "extended cost of materials ratio" rose to 33.9% in the third quarter of 2026 (compared to 31.4% in the same quarter of the previous year), primarily due to higher energy and raw material prices.

Other operating income amounted to EUR 6,349 thousand in the third quarter of 2026, compared to EUR 3,806 thousand in the same quarter of the previous year. The increase is primarily attributable to the effects already described for the nine-month period.

Personnel expenses decreased by EUR 625 thousand in the third quarter of 2026 compared to the same quarter of the previous year, to EUR 42,620 thousand. This was primarily due to lower additions to provisions for bonuses and profit-sharing.

Mainly due to higher waste disposal costs, other operating expenses increased by EUR 2,596 thousand compared to the same quarter of the previous year, reaching EUR 27,554 thousand.

Overall, these developments in the third quarter of 2026 resulted in EBITDA of EUR 28,698 thousand, which was slightly below the prior-year quarter's figure of EUR 29,724 thousand. The EBITDA margin decreased accordingly from 21.7% to 20.5%.

Depreciation and amortization increased by EUR 2,901 thousand compared to the same quarter of the previous year to EUR 9,556 thousand due to completed capital expenditures.

Primarily due to higher interest expenses resulting from borrowing, the financial result decreased to EUR -593 thousand, compared with EUR -435 thousand in the prior year.

Tax expense decreased to EUR 5,002 thousand (same quarter of the prior year: EUR 6,297 thousand) as a result of lower earnings before taxes. The Group tax rate was 27% (prior year: 28%).

As a result of higher depreciation and amortization and increased financing costs, consolidated result for the third quarter of 2026 was EUR 13,547 thousand, down EUR 2,790 thousand from the same quarter of the previous year.

Earnings per share for the third quarter of 2026 amounted to EUR 1.34 (prior year: EUR 1.61). The calculation was based on a weighted average of 10,082,118 shares outstanding (same quarter of the prior year: 10,102,730 shares).

1.9 FINANCIAL POSITION

CONSOLIDATED CASH FLOW STATEMENT (IFRS, UNAUDITED)

in EUR thousand	3rd quarter 2025	3rd quarter 2026	January 1 – September 30, 2025	January 1 – September 30, 2026
Cash flow from operating activities	**44,259**	**46,683**	**115,497**	**97,387**
Cash outflow from investing activities	-26,935	-36,344	-67,430	-117,570
Free cash flow	**17,324**	**10,339**	**48,067**	**-20,183**
Cash inflows/outflows from financing activities	-2,065	-12,113	-29,404	12,327
Net decrease/increase in cash and cash equivalents	**15,259**	**-1,774**	**18,663**	**-7,856**

DEVELOPMENT IN THE 9-MONTH PERIOD FROM JANUARY 1 TO SEPTEMBER 30, 2026

The first nine months of 2026 were characterized by strong operating cash flow and high capital expenditures. The Alzchem Group's financial position remained stable.

From operating activities, Alzchem generated a cash inflow of EUR 97,387 thousand in the first nine months of fiscal year 2026, which was EUR 18,110 thousand lower than the prior-year figure. This development was primarily driven by two opposing effects. On the one hand, customer grants related to the expansion of nitroguanidine production capacity, at EUR 11,427 thousand, were significantly lower than in the same period of the previous year (EUR 55,537 thousand). On the other hand, the planned reduction in inventories had a positive effect on operating cash flow. These inventories had been purposefully built up in the prior year to ensure supply during the carbide furnace renovation. Adjusted for the effects of customer grants and the reduction in net working capital, there was a significant improvement in operating cash flow compared to the prior year.

Alzchem continues to grow and make significant investments. This is also reflected in the increase in cash outflows for investing activities. These amounted to EUR 117,570 thousand during the reporting period, which was EUR 50,140 thousand higher than the previous year's level. This increase is primarily attributable to growth investments in the Defense (nitroguanidine) and Human Nutrition (Creapure® and Creavitalis®) divisions, as well as to the renovation of the carbide furnace.

As a result of the high level of capital expenditures, free cash flow amounted to EUR -20,183 thousand, falling short of the prior-year figure of EUR 48,067 thousand.

To finance the extensive growth investments, a new financing structure was established in the second quarter of 2026. An agreement was reached with Alzchem's existing banking syndicate for up to EUR 100 million in debt financing. This includes new loans totaling EUR 80 million and additional available funds of EUR 20 million, which can be drawn upon as needed. EUR 30 million of the newly disbursed repayment loans were used for the early, interest-optimized repayment of loans that would have matured at the end of 2027 or the beginning of 2028. This refinancing lays the foundation for Alzchem's continued growth.

In total, Alzchem recorded a cash inflow from financing activities of EUR 12,327 thousand during the reporting period. This was EUR 41,731 thousand higher than in the prior year. In addition to the restructuring of financing described above, repayments totaling EUR 4,750 thousand (prior year: EUR 6,000 thousand) were made on existing loans. A total of EUR 21,260 thousand (previous year: EUR 18,190 thousand) was paid out as dividends to the shareholders of Alzchem Group AG. In addition, EUR 10,049 thousand (previous year: EUR 3,605 thousand) was paid out for the purchase of treasury shares as part of the share buyback program.

As of September 30, 2026, cash and cash equivalents totaled EUR 63,845 thousand, which was EUR 7,875 thousand lower than the level as of December 31, 2025.

DEVELOPMENT IN THE THIRD QUARTER OF 2026

In the third quarter of 2026, Alzchem generated cash flow from operating activities of EUR 46,683 thousand, representing an increase of EUR 2,424 thousand compared to the same quarter of the previous year (EUR 44,259 thousand). This growth is primarily attributable to a reduction in inventory levels.

Cash outflows for investing activities amounted to EUR 36,344 thousand in the reporting quarter, which was EUR 9,409 thousand higher than the prior-year level. The increase is primarily attributable to the growth and modernization investments already described for the nine-month period.

The resulting free cash flow amounted to EUR 10,339 thousand in the third quarter of 2026, compared to EUR 17,324 thousand in the same quarter of the prior year.

Financing activities resulted in a cash outflow of EUR 12,113 thousand in the third quarter of 2026. By comparison, the cash outflow in the same quarter of the previous year was EUR 2,065 thousand. The higher cash outflow compared to the same quarter of the previous year was primarily attributable to the implementation of the share buyback program.

As of September 30, 2026, cash and cash equivalents totaled EUR 63,845 thousand, which was EUR 1,850 thousand lower than the level as of June 30, 2026.

1.10 NET ASSETS

CONSOLIDATED BALANCE SHEET (IFRS, UNAUDITED)

in EUR thousand	12/31/2025	09/30/2026	Change
Assets			
Intangible assets	3,529	4,018	489
Property, plant, and equipment	276,980	353,611	76,631
Lease usage rights	2,992	1,767	-1,225
Financial assets	6	6	0
Other receivables and other assets	21,801	13,359	-8,442
Deferred tax assets	15,711	14,060	-1,651
Non-current assets	**321,019**	**386,821**	**65,802**
Inventories	116,004	104,581	-11,423
Trade receivables	73,416	77,371	3,955
Other receivables and other assets	35,201	40,928	5,727
Income tax claims	319	165	-154
Cash and cash equivalents	71,720	63,845	-7,875
Current assets	**296,660**	**286,890**	**-9,770**
Total assets	**617,679**	**673,711**	**56,032**
Capital			
Equity	258,231	280,590	22,359
Non-current liabilities	240,544	274,723	34,179
Current liabilities	118,904	118,398	-506
Equity and liabilities	**617,679**	**673,711**	**56,032**

As of September 30, 2026, Alzchem's balance sheet total amounted to EUR 673,711 thousand, an increase of EUR 56,032 thousand compared to December 31, 2025.

The strong investment activity is also reflected in the significant increase in balance sheet total. Non-current assets increased by EUR 65,802 thousand to EUR 386,821 thousand. This was primarily driven by a EUR 76,631 thousand rise in property, plant, and equipment, mainly due to capacity expansions for nitroguanidine and creatine, as well as the renovation of the carbide furnace. In particular, the EUR 8,442 thousand decrease in other receivables and other assets had an offsetting effect.

Current assets decreased by EUR 9,770 thousand to EUR 286,890 thousand. The main reasons for this were a decline in inventories of EUR 11,423 thousand and a reduction in cash and cash equivalents of EUR 7,875 thousand. Conversely, trade receivables increased by EUR 3,955 thousand, and other receivables and assets grew by EUR 5,727 thousand. The decrease in inventories is primarily related to the reduction of stock built up as of December 31, 2025, in anticipation of the planned renovation of the carbide furnace. The increase in other receivables and other assets is mainly due to the portion of customer grants due in the short term in connection with the expansion of nitroguanidine capacities. The development of cash and cash equivalents is explained in more detail in the section on the financial position.

Equity increased by EUR 22,359 thousand compared to December 31, 2025, to EUR 280,590 thousand. The main driver of this development was the consolidated result of EUR 48,372 thousand generated during the reporting period. Offsetting this were, in particular, the dividend of EUR 21,260 thousand approved by the Annual General Meeting on May 5, 2026, and paid out on May 8, 2026, as well as the buyback of treasury shares. During the reporting period, treasury shares totaling EUR 10,043 thousand were repurchased. As a result, the company held a total of 114,987 treasury shares as of September 30, 2026. In addition, the actuarial revaluation of pension obligations had a positive effect on equity. The adjustment of actuarial assumptions, particularly the interest rate, resulted in an increase in equity of EUR 5,370 thousand after taking tax effects into account. Despite the absolute growth in equity, the equity ratio remained largely stable due to the simultaneous significant increase in balance sheet total.

Non-current liabilities increased by EUR 34,179 thousand compared to December 31, 2025, to EUR 274,723 thousand. This development is primarily attributable to Alzchem's new financing structure established in the second quarter of 2026. Taking into account the early repayment of existing loan obligations, the refinancing led to an increase in non-current financial liabilities of EUR 50 million. Scheduled repayments of existing loans, among other factors, had an offsetting effect. Non-current contract liabilities amounted to EUR 84,754 thousand as of September 30, 2026, representing a decrease of EUR 3,345 thousand from the figure as of December 31, 2025. Pension obligations, which are also included in non-current liabilities, are significantly influenced by changes in actuarial parameters. Changes in these parameters are recognized in other comprehensive income in accordance with IFRS and thus have a direct impact on equity. The interest rate is of particular importance in this context. As the interest rate rises, the present value of pension obligations generally decreases, while a falling interest rate has the opposite effect. Pension provisions decreased by EUR 6,268 thousand compared to December 31, 2025. This decline is primarily attributable to the increase in the interest rate from 4.10% as of December 31, 2025, to 4.70% as of September 30, 2026.

The interest rate developed as follows:

in %	2021	2022	2023	2024	2025	Q3/2025	1st half of 2026	Q3/2026
Interest rate	1.00	3.70	3.20	3.40	4.10	3.80	4.10	4.70

No new employees have been included in the pension plan since 2007. Due to the age structure of the plan beneficiaries, current pension payments are gradually increasing. Since future payments are spread over a long-term forecast period of approximately 30 years, this has no material impact on Alzchem's financial performance. In the first nine months of 2026, pension payments totaled EUR 2,160 thousand, compared to EUR 1,986 thousand in the same period of the previous year.

Historically, these pension payments have developed as follows:

in EUR thousand	2021	2022	2023	2024	2025	9M 2025	1st half of 2026	9M 2026
Pensions paid	-1,516	-1,685	-1,930	-2,265	-2,614	-1,986	-1,488	-2,160

As of the current reporting date, current liabilities amounted to EUR 118,398 thousand, which was nearly at the same level as the EUR 118,904 thousand reported as of December 31, 2025. Decreases in trade payables and other provisions were offset in particular by higher current contractual liabilities and current loan liabilities.

2. Development in the segments

2.1 SPECIALTY CHEMICALS SEGMENT

in EUR thousand	3rd quarter 2025	3rd quarter 2026	January 1 – September 30, 2025	January 1 – September 30, 2026
External sales	86,978	98,490	281,618	312,742
EBITDA	**24,117**	**27,470**	**78,012**	**91,548**
EBITDA margin	**27.7%**	**27.9%**	**27.7%**	**29.3%**
Inventories	57,509	59,849	57,509	59,849

DEVELOPMENT IN THE 9-MONTH PERIOD FROM JANUARY 1 TO SEPTEMBER 30, 2026

The Specialty Chemicals segment seamlessly continued its sustained growth trajectory during the reporting period. In the first nine months of fiscal year 2026, sales from high-value ingredients rose to EUR 312,742 thousand, representing an increase of EUR 31,124 thousand, or 11%, compared to the prior year. This development was driven in particular by sustained high demand and positive sales volume growth. Business performance was in line with management's expectations.

As expected, the largest contribution to sales growth came from the Human Nutrition (Creapure® and Creavitalis®) and Defense (nitroguanidine) divisions. The Human Nutrition division again recorded growth in the first nine months of fiscal year 2026 compared to the same period last year. The increase in sales was made possible in particular by the capacity expansion that went into operation in the third quarter of 2025. This development is supported by the continued high demand for creatine "Made in Germany" as well as additional market potential outside the sports nutrition sector. To meet the rising demand sustainably, Alzchem is currently constructing a new, largely automated production facility for creatine and its precursors. The project remains on track within the originally defined timeframe. Phased commissioning is scheduled to begin in the second half of 2027 and will significantly support Alzchem's continued growth.

Growth also continued in the defense sector during the reporting period. The key driver of the sales increase was the sustained high demand for nitroguanidine. To secure current and anticipated demand over the long term, Alzchem is consistently expanding its production capacity. The new production facilities in Germany were commissioned on schedule and are currently being ramped up. As a result, Alzchem now has the necessary capacity to fully meet customer demand.

The highly specialized business of custom synthesis using Alzchem's multi-purpose plants continued to perform well and resulted in high and stable utilization of the production facilities.

The segment's encouraging sales performance was reflected in a disproportionately large increase in profitability. EBITDA grew by 17% to EUR 91,548 thousand in the first nine months of 2026 (prior year: EUR 78,012 thousand). Accordingly, the EBITDA margin improved significantly from 27.7% to 29.3%.

The segment's inventories amounted to EUR 59,849 thousand, up from EUR 57,509 thousand in the prior year. The planned increase in inventories is primarily attributable to the segment's expanded business activity.

DEVELOPMENT IN THE THIRD QUARTER OF 2026

Looking at the third quarter of 2026, sales development showed a similar pattern to that of the first nine months. Sales totaled EUR 98,490 thousand, representing an increase of EUR 11,512 thousand, or 13%, over the prior year.

The development in key earnings metrics for the third quarter of 2026 is also comparable to that of the nine-month period. EBITDA amounted to EUR 27,470 thousand, representing an increase of EUR 3,353 thousand, or 14%, compared to the previous year. Accordingly, the EBITDA margin rose in the third quarter of 2026 from 27.7% to 27.9%.

When considering inventories as of the reporting date, the same statement applies as for the nine-month period.

2.2 BASICS & INTERMEDIATES SEGMENT

in EUR thousand	3rd quarter 2025	3rd quarter 2026	January 1 – September 30, 2025	January 1 – September 30, 2026
External sales	43,309	34,115	121,552	109,465
EBITDA	**3,754**	**2,028**	**5,068**	**2,008**
EBITDA margin	**8.7%**	**5.9%**	**4.2%**	**1.8%**
Inventories	56,732	42,896	56,732	42,896

DEVELOPMENT IN THE 9-MONTH PERIOD FROM JANUARY 1 TO SEPTEMBER 30, 2026

In the Basics & Intermediates segment, sales for the first nine months of fiscal year 2026 totaled EUR 109,465 thousand, which was EUR 12,087 thousand below the prior-year level. The decline in sales was in line with expectations and resulted primarily from lower sales volumes. Key factors included persistently weak demand in the agricultural sector as well as continued high competitive and pricing pressure from Asian suppliers in the pharmaceutical applications segment. By contrast, the metallurgical business saw positive momentum due to the improved economic conditions in the European steel industry.

As expected, the decline in sales in the Basics & Intermediates segment was also reflected in earnings performance. EBITDA for the reporting period amounted to EUR 2,008 thousand, which was EUR 3,060 thousand below the prior-year level. Accordingly, the EBITDA margin decreased by 2.4 percentage points to 1.8%. In addition to weak demand development in individual sales markets, earnings performance was particularly impacted by the year-over-year increase in electricity and raw material prices. The main factors behind this were the escalating geopolitical tensions in the Middle East, which led to increased volatility in the international energy and raw materials markets as well as significant price increases.

The segment's inventories, at EUR 42,896 thousand, were significantly below the prior-year level of EUR 56,732 thousand. After inventories had been gradually built up in 2025 in preparation for the carbide furnace renovation, a scheduled reduction in inventories took place during the reporting period.

DEVELOPMENT IN THE THIRD QUARTER OF 2026

The third quarter of 2026 presented a picture similar to that of the first nine months. Sales amounted to EUR 34,115 thousand, which was EUR 9,194 thousand below the prior-year level. Segment EBITDA in the third quarter of 2026 was EUR 2,028 thousand, which was EUR 1,726 thousand below the prior-year level. Accordingly, the EBITDA margin also decreased by 2.8 percentage points to 5.9%. The reasons for this correspond to the market and cost developments explained in the nine-month period.

With regard to inventories as of the reporting date, the same statement applies as for the nine-month period.

2.3 OTHER & HOLDING SEGMENT

in EUR thousand	3rd quarter 2025	3rd quarter 2026	January 1 – September 30, 2025	January 1 – September 30, 2026
External sales	6,979	7,277	21,655	21,578
EBITDA	**596**	**460**	**954**	**148**
EBITDA margin	**8.5%**	**6.3%**	**4.4%**	**0.7%**
Inventories	5,843	5,555	5,843	5,555

DEVELOPMENT IN THE 9-MONTH PERIOD FROM JANUARY 1 TO SEPTEMBER 30, 2026

Sales for the Other & Holding segment, at EUR 21,578 thousand, were roughly on par with the prior-year level of EUR 21,655 thousand. The slight decrease is primarily attributable to reduced power grid fees paid by chemical park customers, which Alzchem is permitted to pass on to customers under electricity regulations.

The segment's EBITDA followed the trend in sales and, at EUR 148 thousand, was below the prior-year level.

Inventories as of the reporting date for the period under review totaled EUR 5,555 thousand. These consist primarily of raw materials and supplies held in stock by the chemical park customers.

DEVELOPMENT IN THE THIRD QUARTER OF 2026

In the third quarter of 2026, sales increased by EUR 298 thousand compared to the same quarter of the previous year, reaching EUR 7,277 thousand, primarily due to catch-up effects from the billing of electricity grid fees to third-party customers as well as increased demand from chemical park customers. EBITDA amounted to EUR 460 thousand, which was EUR 136 thousand below the prior-year figure. The decline in earnings is primarily attributable to increased expenses related to measures for the modernization and further development of the infrastructure at the Trostberg site.

With regard to inventories as of the reporting date, the same statement applies as for the nine-month period.

3. Sustainability at Alzchem

In its combined management report as of December 31, 2025, Alzchem reported on the company's non-financial matters in partial accordance with the European Sustainability Reporting Standards (ESRS) and underwent a voluntary limited assurance engagement in accordance with ISAE 3000. There have been no fundamental changes to the statements in this sustainability statement during the third quarter of 2026. However, as a responsible company, we also wish to inform our stakeholders about the current sustainability activities for fiscal year 2026 in this quarterly statement as of September 30, 2026. To cover the entire nine-month period, this report also includes activities that were already described in Alzchem Group AG's half-year financial report as of June 30, 2026.

3.1 EXPANSION OF THE EV CHARGING INFRASTRUCTURE AT THE TROSTBERG, SCHALCHEN, AND HART SITES

Alzchem employees can charge their electric vehicles free of charge during working hours, as long as this remains permissible under applicable tax regulations. As this offer is being used more and more, Alzchem is investing in additional charging stations for electric vehicles this year at the Trostberg, Schalchen, and Hart sites. In Trostberg, 18 additional charging points are currently planned; in Schalchen and Hart, four and eight more, respectively – with the option to moderately increase the number if necessary.

In this way, Alzchem supports its workforce's commitment to environmental sustainability. The energy generated on-site reduces reliance on the public grid and simultaneously improves the carbon footprint of Alzchem's products. This initiative helps Alzchem employees choose an electric vehicle when purchasing a new personal car.

3.2 SUSTAINABLE EMPLOYEE MOBILITY, INCLUDING BICYCLES: ALZCHEM NAMED A "MOBILITY CHAMPION"

During the reporting period, Alzchem was named a "Mobility Champion" as part of a recent evaluation by JobRad. The award is based on a metric that reflects the ratio of JobRad-eligible employees to the number of new leasing contracts concluded in 2025.

The award underscores the high level of acceptance of the sustainable employee mobility program among the workforce. Through the company bicycle leasing program, employees have the opportunity to use bicycles and e-bikes under attractive terms. The deferred compensation model allows for both work-related and personal use, while Alzchem also covers the costs of comprehensive insurance, among other benefits.

Promoting climate-friendly mobility solutions is an integral part of Alzchem's ESG strategy. Particularly in the environmental sphere, the increasing use of JobRad offerings contributes to reducing indirect CO_2 emissions within the corporate environment. At the same time, the program enhances the company's appeal as an employer and supports a healthy, active lifestyle among employees.

alzchem.com/en/sustainability/

alzchem.com/en/company/news/alzchem-honored-as-a-mobility-champion/

3.3 PRACTICAL CLIMATE PROTECTION: EMINEX® RESEARCH PROJECT HONORED

The EMeRGE research project was awarded the Silver Biogas Innovation Prize in the Science category in 2026. The project focuses on Eminex®, a product from Alzchem. The award ceremony took place on May 20 and 21, 2026, at the Biogas Innovation Congress in Osnabrück, hosted by the German Federal Environmental Foundation (Deutsche Bundesstiftung Umwelt, DBU). The award recognizes solutions that measurably advance the biogas industry and agriculture – for example, in the area of climate protection.

An expert jury selects 15 ideas to be presented to a specialist audience. The award is given in the categories of Science and Business, with the Science Award offered in gold, silver, and bronze, totaling EUR 10 thousand. The award recognized the results of the EMeRGE research project conducted by Alzchem and the Leibniz Institute for Agricultural Engineering and Bioeconomy (ATB). The study shows that Eminex® significantly reduces methane emissions during the storage of manure and fermentation residues, stabilizes plant-available nitrogen, and can increase methane yields by up to 11% in subsequent biogas digestion of the manure when stored for at least 14 days. At the conference, Dr. Christiane Herrmann (ATB), project manager of EMeRGE, presented the key findings and the benefits for farms and biogas plants.

The award recognized a practical climate protection solution: Eminex® is a calcium cyanamide-based additive that is mixed in small doses into manure and fermentation residues (substrate residues from biogas plants). During storage, it can significantly reduce methane formation in farm manure, thereby lowering storage emissions. At the same time, the treatment helps to better stabilize nutrients – especially nitrogen – in the manure. When the material is later used in a biogas plant, the full methane potential is still preserved. The measure can be implemented without requiring any additional structural modifications to the storage facility.

3.4 ALZCHEM ONCE AGAIN RANKS AMONG THE TOP 5% OF COMPANIES EVALUATED WORLDWIDE BY ECOVADIS

In 2026, Alzchem once again underwent EcoVadis' independent CSR rating. With a score of 85 out of 100, Alzchem was awarded the Gold Medal and is thus among the top 5% of companies worldwide evaluated by EcoVadis over the past twelve months.

The assessment covers the areas of environment, labor and human rights, ethics, and sustainable procurement. Particularly encouraging is the progress made in labor and human rights (96 points), ethics (87 points), and sustainable procurement (85 points). Alzchem improved in these areas compared to the previous assessment. In the area of the environment, the company achieved 73 points. The result confirms Alzchem's holistic ESG approach and the continuous advancement of its sustainability initiatives.

alzchem.com/en/company/news/eminex-research-project-award/

alzchem.com/en/company/news/ecovadis-2026/

3.5 “MY SHARE OF ALZCHEM”: HIGH PARTICIPATION IN THE EMPLOYEE PARTICIPATION PROGRAM

As part of the “My share of Alzchem” employee participation program, eligible employees were able to acquire a stake in the company for the second time through various stock packages and also receive additional shares sponsored by Alzchem. A total of 880 employees took advantage of the offer. This corresponds to a participation rate of approximately 54%.

The high participation rate demonstrates the strong sense of connection many employees feel toward Alzchem and enables them to support the company’s continued development as shareholders and owners. Alzchem Group AG had acquired the shares used for the program through share buyback programs.

3.6 CREAPURE® AND FC BAYERN BASKETBALL CONTINUE THEIR PARTNERSHIP



The partnership between Creapure® and FC Bayern Basketball has been extended and further expanded for the season 2026/27. Creapure® remains the official Gold Partner and official creatine partner. In addition, the collaboration is being expanded to include the FC Bayern Basketball cheerleaders, thereby further strengthening the brand’s presence in the sports community. Both partners share a commitment to performance, quality, and continuous improvement.

FC BAYERN MÜNCHEN BASKETBALL | Creapure® Offizieller Kreatin Partner

alzchem.com/en/company/news/creapure-fcbb-contract-renewal/

4. Forecast report

The following table provides an overview of the Group's financial performance indicators projected in the consolidated financial statements as of December 31, 2025, for fiscal year 2026:

	Unit	2025	Forecast 2026
Group sales	EUR million	562.1	Growing to around EUR 600 million
Adjusted EBITDA*	EUR million	116.5	Growing to around EUR 126 million
Adjusted EBITDA margin*	%	20.7	Slightly growing to around 21.0%
Inventories	EUR million	116.0	Significantly decreasing
Inventory intensity	%	20.6	Slightly decreasing
Equity ratio	%	41.8	Slightly decreasing

* No adjustments were made.

The forecasts for fiscal year 2026 set forth in the consolidated financial statements as of December 31, 2025, can be confirmed in this quarterly statement. For this purpose, the assumptions made in the Annual Report 2025 continue to apply in all material respects.

Overall, the Alzchem Group continues to face a volatile geopolitical environment. Nevertheless, based on current assessments, recent developments, particularly those related to the conflict in Iran, are not expected to have a material impact on the forecast for fiscal year 2026. While this could result in further price increases for energy and selected raw materials, we expect to be able to largely offset these effects in most product areas through hedging or corresponding price adjustments. Additional disruptions to global supply chains are not factored into the forecast.

According to current estimates, the industrial electricity price adopted by the German federal government is expected to have a slightly positive impact on Alzchem's cost structure only from fiscal year 2027 onwards and was therefore not included in the forecast for the current fiscal year. The wage agreement reached in March 2026 for the German chemical and pharmaceutical industries is in line with expectations and has already been fully factored into the forecast assumptions.

The temporarily weaker sales and earnings performance expected in the third quarter of 2026 has been confirmed and was in line with the assumptions of the full-year forecast. Alzchem therefore reaffirms its forecast for fiscal year 2026 unchanged.

5. Events after the balance sheet date

After the balance sheet date of September 30, 2026, the developments described in the section “Development of the Group” regarding the REACH restriction proceedings for calcium cyanamide and the resolution to the new share buyback program took place. Furthermore, no other significant events have occurred as of the date of preparation of this quarterly statement.


Trostberg, October 29, 2026

Alzchem Group AG
The Management Board


Andreas Niedermaier (CEO)


Dr. Jürgen Sans (COO)


Andreas Lösler (CFO)


Martina Spitzer (CSO)

List of abbreviations

AG	Aktiengesellschaft (stock corporation)
EBIT	Earnings before interest and taxes
EBITDA	Earnings before interest, taxes, depreciation and amortization
EU	European Union
EUR	Euro
USA	United States of America

Financial calendar 2027

February 25, 2027*	**Annual Report 2026**
April 29, 2027*	**Q1 Quarterly Statement 2027**
May 5, 2027*	**Annual General Meeting 2027**
July 29, 2027*	**Half-year Financial Report 2027**
October 28, 2027*	**Q3 Quarterly Statement 2027**

* Subject to change

With the QR code you will get to all current events of Alzchem.

alzchem.com/en/investor-relations/events-dates/

Remarks

This quarterly statement may contain forward-looking statements based on current assumptions and forecasts made by the management of Alzchem Group AG. Such statements are subject to risks and uncertainties. These and other factors may cause actual results, financial position, development or performance of the company to differ materially from the estimates made here. The company assumes no liability whatsoever to update such forward-looking statements or to conform them to future events or developments.

In the interests of readability, this quarterly statement does not use the masculine, feminine and diverse (m/f/d) forms of language simultaneously. All references to persons apply equally to all genders.

This quarterly statement is also available in German. In the event of deviations, only the German version is legally binding.

Imprint

PUBLISHER
Alzchem Group AG
Chemiepark Trostberg
Dr.-Albert-Frank-Str. 32
83308 Trostberg
www.alzchem.com

INVESTOR RELATIONS
Sabine Sieber
P + 49 86 21 86 – 2888
F + 49 86 21 86 – 502888
ir@alzchem.com

EDITING
IR4value GmbH

PICTURE CREDITS
Alzchem Group AG
FC Bayern München
Basketball



Alzchem Group AG
CHEMIEPARK TROSTBERG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
P + 49 8621 86-0
info@alzchem.com

alzchem.com